Skip to content

To find out which one of mirena and implanon is better in receiving endometriosis related lower abdominal pain

To compare the efficiency of etonorgestrel releasing contraceptive implant versus that of levonorgestrel releasing intrauterine system in alleviating pain in women affected with endometriosis - Nil

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/12/099485
Enrollment
98
Registered
2025-12-19
Start date
Unknown
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N800- Endometriosis of uterus

Interventions

Intervention1: Levonorgestrel intrauterine device: One group of people with endometriosis related chronic pelvic pain will be given levonorgestrel releasing intrauterine device .It will be inserted in

Sponsors

Riddhi Pushilal
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients having confirmed diagnosis of endometriosis 2.Women with diagnosis of deep endometriosis by TVUS or MRI 3.Those who are on other management for endometriosis will be included after washout period

Exclusion criteria

Exclusion criteria: 1.Women who cannot use either of the two hormonal implants as prescribed by WHO 2.Women who have undergone surgical intervention for symptom management with 2months of enrolment in the study. 3.Women who wish to conceive within the next 12 months. 4.Women who are not otherwise healthy 5.Women who are not willing to keep a menstrual diary to record their bleeding and pain levels 6.Age of the patient is not within 18-45 years 7.If the patient is not willing to follow up in the Out Patient s Department 8.The patient s unwilling to adopt either of the proposed treatment alternative

Design outcomes

Primary

MeasureTime frame
Primary outcome : The primary outcome measures the improvement in the level of pain felt during each cycle of menstruation after the insertion of the implant as compared to the month before. Timepoint: The primary outcome will be measured as improvement in pain levels after 90 days

Secondary

MeasureTime frame
Secondary outcome : The secondary outcome will be the improvement in the quality of life & noncyclic pain after the intervention as compared to before. Timepoint: The secondary outcome will be studied in a span of 90 days

Countries

India

Contacts

Public ContactRiddhi Pushilal

Ipgmer

drgkamilya@gmail.com9830823183

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026